Síntomas intestinales en pacientes que reciben inhibidores de bomba de protones (IBP). Resultados de una encuesta multicéntrica en México
Open accessAbstract
INTRODUCTION: Proton pump inhibitors (PPIs) have been associated with small intestinal bacterial overgrowth (SIBO), which increases with prolonged PPI use, and SIBO has been associated with irritable bowel syndrome (IBS). OBJECTIVE: The aim of the present study was to study the prevalence of bowel symptoms in patients treated with PPIs in Mexico. METHODS: Gastroenterologists in 36 cities surveyed patients treated with PPIs, utilizing an ad hoc questionnaire to determine the presence of bowel symptoms and IBS. RESULTS: Two hundred and fifteen physicians interviewed 1,851 patients. PPI indications were gastritis (48.8%), gastroesophageal reflux (38.5%), peptic ulcer (6.2%), and others (6.5%). A total of 77.5% of the patients received treatment for ≤6 months and 11.9% for ≥1 year. Symptoms were reported in 92.3% of the patients: abnormal bowel habits (90%), bloating (82%), abdominal pain (63%), flatulence (58%), and abdominal discomfort (53%). A total of 67.5% of the patients fit the Rome III criteria for IBS. Symptoms presented in 55.9% of the patients before PPI intake and in 44.1% of the patients after PPI use (P<.005). Constipation (63.8%) predominated in the former, and diarrhea (56.5%) in the latter (P<.0001). The treatments prescribed for managing those symptoms were antispasmodics, antibiotics, prokinetics, and antiflatulents, but patients stated greater satisfaction with antibiotics (mainly rifaximin) (P<.0001). CONCLUSION: The association of PPIs with bowel symptoms and IBS is frequent in Mexico. Diarrhea and bloating predominate, and antibiotics produce the greatest treatment satisfaction, suggesting that SIBO or dysbiosis is the cause of the PPI-related bowel symptoms. However, that remains to be confirmed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
It is likely that PPI use predisposes patients to the development of IBS.
“It is likely that PPI use predisposes patients to the development of IBS[116].”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The burden of selected digestive diseases in the United States
Sandler, R. S., Everhart, J. E., Donowitz, M., Adams, E., Cronin, K., Goodman, C., Gemmen, E., Shah, S., Avdic, A., & Rubin, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.32978 · Cited by 1,512 · see citing works
Rezaie, A. R., Buresi, M. C., Lembo, A. J., Lin, H. C., McCallum, R. W., Rao, S. S. C., Schmulson, M. J., Valdovinos, M. A., Zakko, S. F., & Pimentel, M. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.46 · Cited by 850 · see citing works
Self-citationSystematic review of the risk of enteric infection in patients taking acid suppression
Leonard, J., Marshall, J. K., & Moayyedi, P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01275.x · Cited by 633 · see citing works
for the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469 · see citing works
Canani, R. B., Cirillo, P., Roggero, P., Romano, C., Malamisura, B., Terrin, G., Passariello, A., Manguso, F., Morelli, L., Guarino, A., et al. (2006) · PEDIATRICS · doi:10.1542/peds.2005-1655 · Cited by 395 · see citing works
Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis
Eom, C.-S., Jeon, C. Y., Lim, J.-W., Cho, E.-G., Park, S. M., & Lee, K.-S. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.092129 · Cited by 393 · see citing works
Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-analysis
Lo, W., & Chan, W. W. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.12.011 · Cited by 353 · see citing works
Ford, A. C., Spiegel, B. M. R., Talley, N. J., & Moayyedi, P. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.031 · Cited by 351 · see citing works
Increased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy
Lombardo, L., Foti, M., Ruggia, O., & Chiecchio, A. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.12.022 · Cited by 350 · see citing works
Thorens, J.-J., Froehlich, F., Schwizer, W., Saraga, E. P., Billé, J., Gyr, K. E., Duroux, P., Nicolet, M., Pignatelli, B., Blum, A. L., et al. (1996) · Gut · doi:10.1136/gut.39.1.54 · Cited by 339 · see citing works
Safety of the long-term use of proton pump inhibitors
Thomson, A. B. R. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i19.2323 · Cited by 314 · see citing works
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015
Iwakiri, K., Kinoshita, Y., Habu, Y., Oshima, T., Manabe, N., Fujiwara, Y., Nagahara, A., Kawamura, O., Iwakiri, R., Ozawa, S., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1227-8 · Cited by 284 · see citing works
Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection
Linsky, A. M. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.73 · Cited by 275 · see citing works
Aseeri, M. A., Schroeder, T., Kramer, J., & Zackula, R. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01975.x · Cited by 236 · see citing works
Review article: proton pump inhibitors and bacterial overgrowth
Williams, C., & McColl, K. E. L. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02707.x · Cited by 219 · see citing works
Xie, Y., Bowe, B. C., Li, T., Xian, H., Yan, Y., & Al‐Aly, Z. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.021 · Cited by 201 · see citing works
Duodenal bacterial overgrowth during treatment in outpatients with omeprazole.
Fried, M., Siegrist, H. H., Frei, R., Froehlich, F., Duroux, P., Thorens, J.-J., Blum, A. L., Billé, J., Gonvers, J. J., & Gyr, K. E. (1994) · Gut · doi:10.1136/gut.35.1.23 · Cited by 200 · see citing works
Jacobs, C. E., Coss‐Adame, E., Attaluri, A., Valestin, J., & Rao, S. S. C. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12304 · Cited by 177 · see citing works
A comparison of the gut microbiome between long‐term users and non‐users of proton pump inhibitors
Clooney, A. G., Bernstein, C. N., Leslie, W. D., Vagianos, K., Sargent, M., Laserna‐Mendieta, E. J., Claesson, M. J., & Targownik, L. E. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13568 · Cited by 166 · see citing works
A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
Yu, L., Sun, L., Zhang, X., Li, Y.-Q., Yu, L., Yuan, Z.-Q.-Y., Meng, L., Zhang, H., & Wang, Y. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0532-9 · Cited by 141 · see citing works
Use of Acid-Suppressing Drugs and the Risk of Bacterial Gastroenteritis
Rodríguez, L. A. G., Ruigómez, A., & Panés, J. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.09.010 · Cited by 137 · see citing works
Proton pump inhibitor therapy and potential long-term harm
Corleto, V. D., Festa, S., Giulio, E. D., & Annibale, B. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000031 · Cited by 134 · see citing works
Proton pump inhibitors and the kidney: critical review
Brewster, U. C., & Perazella, M. A. (2007) · Clinical Nephrology · doi:10.5414/cnp68065 · Cited by 129 · see citing works
Compare, D., Pica, L., Rocco, A., De Giorgi, F., Cuomo, R., Sarnelli, G., Romano, M., & Nardone, G. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02419.x · Cited by 122 · see citing works
Bate, C. M., Keeling, P. W. N., O'Morain, C. A., Wilkinson, S. P., Foster, D. N., Mountford, R. A., Temperley, J. M., Harvey, R. F., Thompson, D., & Davis, M. (1990) · Gut · doi:10.1136/gut.31.9.968 · Cited by 118 · see citing works
Safety of long-term PPI therapy
Reimer, C. (2013) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.06.001 · Cited by 117 · see citing works
Studying the Overlap Between IBS and GERD: A Systematic Review of the Literature
Nastaskin, I., Mehdikhani, E., Conklin, J., Park, S., & Pimentel, M. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9306-y · Cited by 98 · see citing works
Spiegel, B. M. R., Chey, W. D., & Chang, L. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01992.x · Cited by 95 · see citing works
Sperber, A. D., & Dekel, R. (2010) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2010.16.2.113 · Cited by 85 · see citing works
Acid-suppressive Drugs and Community-acquired Pneumonia
Rodríguez, L. A. G., Ruigómez, A., Wallander, M.-A. A., & Johansson, S. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181b5f27d · Cited by 71 · see citing works
Use of proton pump inhibitors and subsequent risk of celiac disease
Lebwohl, B., Spechler, S. J., Wang, T. C., Green, P. H. R., & Ludvigsson, J. F. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.08.128 · Cited by 71 · see citing works
What are the effects of proton pump inhibitors on the small intestine?
Fujimori, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.6817 · Cited by 70 · see citing works
Gastric acid‐suppressive therapy and community‐acquired respiratory infections
Laheij, R. J. F., van IJzendoorn, M. C., Janssen, M. J. R., & Jansen, J. B. �. �. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01744.x · Cited by 69 · see citing works
Wang, Y.-F., Chen, Y., Luo, J., Chen, T., Wu, J., & Wang, S. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.101 · Cited by 68 · see citing works
Effect of a Proton Pump Inhibitor Deprescribing Guideline on Drug Usage and Costs in Long-Term Care
Thompson, W., Hogel, M., Li, Y., Thavorn, K., O'Donnell, D. J. P., McCarthy, L. M., Dolovich, L. R., Black, C. D., & Farrell, B. J. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.04.020 · Cited by 63 · see citing works
Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome
de Bortoli, N. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i35.5787 · Cited by 55 · see citing works
Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors
Schnoll‐Sussman, F. H., & Katz, P. O. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0115-5 · Cited by 45 · see citing works
Schmulson, M. J., Bielsa, M. V., Carmona-Sánchez, R., Hernández, A., López‐Colombo, A., López‐Vidal, Y., Peláez‐Luna, M., Remes-Troche, J. M., Tamayo, J. L., & Valdovinos, M. A. (2014) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2014.01.001 · Cited by 38 · see citing works
Self-citationChoung, R. S., Locke, G. R., Schleck, C. D., Zinsmeister, A. R., & Talley, N. J. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12082 · Cited by 21 · see citing works
Heartburn and other related symptoms are independent of body mass index in irritable bowel syndrome
Schmulson, M. J., Pulido, D., Escobar, C., Farfán-Labonne, B. E., Gutiérrez‐Reyes, G., & López-Alvarenga, J. C. (2010) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082010000400002 · Cited by 15 · see citing works
Self-citationClustering and stability of functional lower gastrointestinal symptom after enteric infection
Thabane, M. E., Simunovic, M. R. I., Akhtar‐Danesh, N., Garg, A. X., Clark, W. F., & Marshall, J. K. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01898.x · Cited by 12 · see citing works
Rousseau, M., Catala, A. R., & Blaya, J. (2003) · Brain Injury · doi:10.1080/0269905031000089378 · Cited by 10 · see citing works
Proton pump inhibitor prescribing and costs in a large outpatient clinic.
Hood, W., McJunkin, B., Warnock, A., Girme, A., Smith, N., & Robinson, B. S. (2014) · PubMed · Cited by 6 · see citing works
Saettone, S., Broglia, L., & Occhipinti, P. (2009) · Digestive and Liver Disease · doi:10.1016/s1590-8658(09)60372-8 · Cited by 3 · see citing works
Pica, L., Rocco, A., Caruso, F., Giorgi, F. D., Sarnelli, G., Cuomo, R., & Nardone, G. (2009) · Digestive and Liver Disease · doi:10.1016/s1590-8658(09)60053-0 · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- American Medical Society National Historic Chemical Land- marks. Tagamet ® : Discovery of histamine H2-receptor antagonist [consultado 17 Abr 2017]. Disponible en: http: //www.acs.org/content/acs/en/education/whatischemistry/ landmark/cimetidinetagamet.htlm
- Eun CS, Kim HS, Han DS, et al. PPIS are associated with higher C. difficile infection in critically ill patients compared to H2RA. Un Eur Hastroenterol J. 2013;1:A379.
- Zwolinska Wcislo M, Przybylska Felus M, Piateck Guziewicz A, et al. Small Intestinal bacterial overgrowth and gastrointesti- nal symptoms in celiac disease patients receiving proton pump inhibitors. UEG Journal. 2013;1:A579.
- Sandler RS, Everhart JE, Donowitz M, et al. The burden of selec- ted digestive disease in the United States. Gastroenterology. 2002;122:1500---11.
- Compare D, Pica L, Rocco A, et al. Effect of long-term PPI treat- ment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2010;41:380---6.
Cited by
Sorted by citations
Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified
Bruno, G., Zaccari, P., Rocco, G., Scalese, G., Panetta, C., Porowska, B., Pontone, S., & Severi, C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i22.2706 · Cited by 258 · see citing works
Horvath, A., Leber, B., Feldbacher, N., Steinwender, M., Komarova, I., Rainer, F., Blesl, A., & Stadlbauer, V. (2020) · Scientific Reports · doi:10.1038/s41598-020-59550-x · Cited by 35 · see citing works
Kaji, E., Yoden, A., Otani, M., Okuhira, T., Aomatsu, T., Tamai, H., & Ashida, A. (2020) · Helicobacter · doi:10.1111/hel.12696 · Cited by 31 · see citing works
Malfa, G. A., Giacomo, C. D., Cardia, L., Sorbara, E. E., Mannucci, C., & Calapai, G. (2021) · Phytotherapy Research · doi:10.1002/ptr.7074 · Cited by 21 · see citing works
Mruk-Mazurkiewicz, H., Kulaszyńska, M., Jakubczyk, K., Janda, K., Czarnecka, W., Rębacz‐Maron, E., Zacha, S., Sieńko, J., Zeair, S., Dalewski, B., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11030952 · Cited by 13 · see citing works
Case-control analysis of fundic gland polyps and proton-pump inhibitors. A pathologist's perspective
Velazquez-Dohorn, M., López-Durand, C. F., Candanedo-González, F., Araujo-Villalvazo, E. A., & Gamboa‐Domínguez, A. (2019) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2019.02.014 · Cited by 6 · see citing works
Maev, I. V., Андреев, Д. Н., Shaburov, R. I., Zaborovsky, A. V., Фоменко, А. К., Sokolov, F. S., Tsaregorodtsev, S. V., Devkota, M. K., Dicheva, D. T., Cheremushkin, S. V., et al. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.08.203301 · Cited by 3 · see citing works
Shah, Q., & Soldera, J. (2026) · World Journal of Methodology · doi:10.5662/wjm.v16.i1.107169 · Cited by 4 · see citing works
Velazquez-Dohorn, M., López-Durand, C. F., Candanedo-González, F., Araujo-Villalvazo, E. A., & Gamboa‐Domínguez, A. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2019.02.007 · Cited by 2 · see citing works
García‐Carrasco, M., Pinto, C. M., Munguía‐Realpozo, P., Valderrabano, F. M., Méndez‐Martínez, S., Etchegaray‐Morales, I., Montiel-Jarquín, Á. J., López‐Colombo, A., & Schmulson, M. J. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13693 · Cited by 2 · see citing works
Self-citationShaheen, M. M. A., Hroub, M., & Talahmeh, L. (2024) · Journal of International Medical Research · doi:10.1177/03000605241248041 · Cited by 1 · see citing works
罗, 绪. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381893
Long-term impact of proton pump inhibitors in patients with prolonged treatment in Latin America
Añez, A., Campana, L., González, L., Morán, M., Noriega, M., Sima, F., & Urraca, L. (2025) · SAP Multidisciplinary Open · doi:10.62486/agmu2025195
Iftequar, Y., Bajpai, P., Dav, R., Harshitha, K. S., Chandan, C., Goel, R., Chimkar, S. B., & Chowdhary, R. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04418-7
- Authors
- Schmulson, M. J., & Frati-Munari, A. C.
- Affiliations
- Hospital General de México (MX)
- Hospital Médica Sur (MX)
- Corresponding author
- Schmulson, M.J.
- ORCID
- Schmulson, M.J.
- Venue
- Revista de Gastroenterología de México
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 84
- Issue
- 1
- Pages
- 44-51
- ISSN
- 0375-0906 (ISSN-L)
- OpenAlex
- W2801805133
- Cited by
- 14
- References
- 45
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 2 · 2019: 4
- FWCI
- 1.67
- Type
- journal article
- Language
- es
- Open access
- gold
- doi.org
- Licence
- Locations
- Revista de Gastroenterología de México (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- proton pump inhibitors, irritable bowel syndrome, small intestinal bacterial overgrowth, bowel symptoms, bloating, diarrhea, constipation, dysbiosis, rifaximin, antibiotic therapy, Rome III criteria, adverse drug reactions, Mexico
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Gastrointestinal Diseases, Humans, Male, Mexico, Middle Aged, Surveys and Questionnaires, Prevalence, Patient Satisfaction, Irritable Bowel Syndrome, Proton Pump Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
